GLP-1
Denmark’s Novo Nordisk is acquiring New Jersey-based Emisphere Technologies in a deal worth about $1.8 billion. Novo Nordisk and Emisphere have been partnered since 2007.
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.
Galapagos NV and Servier reported that their ROCELLA Phase II clinical trial of GLPG1972/S201086 failed to meet its primary endpoint in osteoarthritis knee repair.
A new 10,000 square foot facility in Marlborough, MA will allow StageBio to offer their expanded histopathology expertise and grow the company’s reach across the greater Boston region.
A new study published in the August 26 edition of Science Advances shows that the effectiveness of a two-pronged Type 2 diabetes treatment improves when drugs are linked by a heat-sensitive tether.
Merck entered into an exclusive licensing deal with Hanmi Pharmaceutical for the development, manufacture and commercialization of efinopegdutide for nonalcoholic steatohepatitis (NASH).
With phase III trials underway and Fast Track designation from the FDA, “It’s, conservatively, at least one year ahead of everyone else’s,” John Temperato, president and CEO, told BioSpace.
It was a busy week for clinical trial announcements. Here’s a look.
Data presented at the virtual American Diabetes Association meeting has Pfizer excited about the promise of its GLP-1R Agonist PF-06882961.
Philadelphia, PA – Oncoceutics announced a Brown University award of $3.4 million that will be used to support a group of research teams for preclinical research, IND-enabling studies and a first-in-human clinical trial for Oncoceutics’ imipridone ONC212.
PRESS RELEASES